Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.

Sinn BV, Weber KE, Schmitt WD, Fasching PA, Symmans WF, Blohmer JU, Karn T, Taube ET, Klauschen F, Marmé F, Schem C, Stickeler E, Ataseven B, Huober J, von Minckwitz G, Seliger B, Denkert C, Loibl S.

Breast Cancer Res. 2019 Dec 11;21(1):142. doi: 10.1186/s13058-019-1231-z.

2.

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.

Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching PA, Lederer B, Denkert C, Schneeweiss A, Braun S, Salat CT, Rezai M, Blohmer JU, Zahm DM, Jackisch C, Gerber B, Klare P, Kümmel S, Schem C, Paepke S, Schmutzler R, Rhiem K, Penn S, Reid J, Nekljudova V, Hartman AR, von Minckwitz G, Untch M.

Ann Oncol. 2018 Dec 1;29(12):2341-2347. doi: 10.1093/annonc/mdy460.

3.

A common goodness-of-fit framework for neural population models using marked point process time-rescaling.

Tao L, Weber KE, Arai K, Eden UT.

J Comput Neurosci. 2018 Oct;45(2):147-162. doi: 10.1007/s10827-018-0698-4. Epub 2018 Oct 8.

4.

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.

Fasching PA, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Costa SD, Blohmer JU, Fehm T, Huober J, Liedtke C, Weinshilboum RM, Wang L, Ingle JN, Müller V, Nekljudova V, Weber KE, Rack B, Rübner M, von Minckwitz G, Couch FJ.

J Clin Oncol. 2018 Aug 1;36(22):2281-2287. doi: 10.1200/JCO.2017.77.2285. Epub 2018 May 23.

5.

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.

Engel C, Rhiem K, Hahnen E, Loibl S, Weber KE, Seiler S, Zachariae S, Hauke J, Wappenschmidt B, Waha A, Blümcke B, Kiechle M, Meindl A, Niederacher D, Bartram CR, Speiser D, Schlegelberger B, Arnold N, Wieacker P, Leinert E, Gehrig A, Briest S, Kast K, Riess O, Emons G, Weber BHF, Engel J, Schmutzler RK; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).

BMC Cancer. 2018 Mar 7;18(1):265. doi: 10.1186/s12885-018-4029-y.

6.

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.

Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt WD, Blohmer JU, Karn T, Pfitzner BM, Kümmel S, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching PA, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Loibl S.

Lancet Oncol. 2018 Jan;19(1):40-50. doi: 10.1016/S1470-2045(17)30904-X. Epub 2017 Dec 7.

PMID:
29233559
7.

Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.

van Mackelenbergh MT, Denkert C, Nekljudova V, Karn T, Schem C, Marmé F, Stickeler E, Jackisch C, Hanusch C, Huober J, Fasching PA, Blohmer JU, Kümmel S, Müller V, Schneeweiss A, Untch M, von Minckwitz G, Weber KE, Loibl S.

Breast Cancer Res Treat. 2018 Jan;167(1):59-71. doi: 10.1007/s10549-017-4480-5. Epub 2017 Sep 5.

PMID:
28875243
8.

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.

van Rossum AGJ, Schouten PC, Weber KE, Nekljudova V, Denkert C, Solbach C, Köhne CH, Thomssen C, Forstbauer H, Hoffmann G, Kohls A, Schmatloch S, Schem C, von Minckwitz G, Karn T, Möbus VJ, Linn SC, Loibl S, Marmé F.

Breast Cancer Res Treat. 2017 Dec;166(3):775-785. doi: 10.1007/s10549-017-4444-9. Epub 2017 Aug 18.

PMID:
28822007
9.

More Than Only Skin Deep: Appearance Self-Concept Predicts Most of Secondary School Students' Self-Esteem.

Baudson TG, Weber KE, Freund PA.

Front Psychol. 2016 Oct 18;7:1568. eCollection 2016.

10.

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.

Martin M, Brase JC, Ruiz A, Prat A, Kronenwett R, Calvo L, Petry C, Bernard PS, Ruiz-Borrego M, Weber KE, Rodriguez CA, Alvarez IM, Segui MA, Perou CM, Casas M, Carrasco E, Caballero R, Rodriguez-Lescure A.

Breast Cancer Res Treat. 2016 Feb;156(1):81-9. doi: 10.1007/s10549-016-3725-z. Epub 2016 Feb 24.

11.

Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.

Blank PR, Filipits M, Dubsky P, Gutzwiller F, Lux MP, Brase JC, Weber KE, Rudas M, Greil R, Loibl S, Szucs TD, Kronenwett R, Schwenkglenks M, Gnant M.

Pharmacoeconomics. 2015 Feb;33(2):179-90. doi: 10.1007/s40273-014-0227-x.

12.

Effect of BMI on cardiovascular and metabolic syndrome risk factors in an Appalachian pediatric population.

Weber KE, Fischl AF, Murray PJ, Conway BN.

Diabetes Metab Syndr Obes. 2014 Sep 25;7:445-53. doi: 10.2147/DMSO.S68283. eCollection 2014.

13.

Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.

Martin M, Brase JC, Calvo L, Krappmann K, Ruiz-Borrego M, Fisch K, Ruiz A, Weber KE, Munarriz B, Petry C, Rodriguez CA, Kronenwett R, Crespo C, Alba E, Carrasco E, Casas M, Caballero R, Rodriguez-Lescure A.

Breast Cancer Res. 2014 Apr 12;16(2):R38. doi: 10.1186/bcr3642.

14.

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.

Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Fisch K, Kronenwett R, Gnant M, Filipits M; Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Br J Cancer. 2013 Dec 10;109(12):2959-64. doi: 10.1038/bjc.2013.671. Epub 2013 Oct 24.

15.

Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test.

Kronenwett R, Bohmann K, Prinzler J, Sinn BV, Haufe F, Roth C, Averdick M, Ropers T, Windbergs C, Brase JC, Weber KE, Fisch K, Müller BM, Schmidt M, Filipits M, Dubsky P, Petry C, Dietel M, Denkert C.

BMC Cancer. 2012 Oct 5;12:456. doi: 10.1186/1471-2407-12-456.

16.

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.

Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M; Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Ann Oncol. 2013 Mar;24(3):640-7. doi: 10.1093/annonc/mds334. Epub 2012 Oct 3.

17.

Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections.

Müller BM, Brase JC, Haufe F, Weber KE, Budzies J, Petry C, Prinzler J, Kronenwett R, Dietel M, Denkert C.

J Clin Pathol. 2012 Jul;65(7):660-2. doi: 10.1136/jclinpath-2012-200716. Epub 2012 Mar 23.

18.

Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay.

Denkert C, Kronenwett R, Schlake W, Bohmann K, Penzel R, Weber KE, Höfler H, Lehmann U, Schirmacher P, Specht K, Rudas M, Kreipe HH, Schraml P, Schlake G, Bago-Horvath Z, Tiecke F, Varga Z, Moch H, Schmidt M, Prinzler J, Kerjaschki D, Sinn BV, Müller BM, Filipits M, Petry C, Dietel M.

Virchows Arch. 2012 Mar;460(3):251-9. doi: 10.1007/s00428-012-1204-4. Epub 2012 Feb 28.

19.

A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.

Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M; EP Investigators.

Clin Cancer Res. 2011 Sep 15;17(18):6012-20. doi: 10.1158/1078-0432.CCR-11-0926. Epub 2011 Aug 1.

20.

Microarray analysis of replicate populations selected against a wing-shape correlation in Drosophila melanogaster.

Weber KE, Greenspan RJ, Chicoine DR, Fiorentino K, Thomas MH, Knight TL.

Genetics. 2008 Feb;178(2):1093-108. doi: 10.1534/genetics.107.078014. Epub 2008 Feb 1.

21.

Recurrent spontaneous "neuroleptic malignant syndrome" in the absence of neuroleptic medication in probable dementia with Lewy bodies.

Weber KE, Linker RA, Lorenz R, Muellges W, Naumann M, Reiners K, Classen J.

J Neurol. 2005 Sep;252(9):1122-4. Epub 2005 Mar 14. No abstract available.

PMID:
15765193
22.

Aerial performance of Drosophila melanogaster from populations selected for upwind flight ability.

Marden JH, Wolf MR, Weber KE.

J Exp Biol. 1997 Nov;200(Pt 21):2747-55.

23.

Achieving sustainable agriculture through recognizing gender roles: some salient points.

Regmi PP, Weber KE.

Gend Technol Dev. 1997 May-Aug;1(2):225-45.

PMID:
12179924
25.

Issues in natural resources management in developing countries.

Thapa GB, Weber KE.

Nat Resour Forum. 1994 May;18(2):115-23.

PMID:
12289879
26.

Reflection of Confucianism, Hinduism, and Buddhism on gender relations and gender specific occupation in Thai society.

Shrestha M, Weber KE.

Warasan Prachakon Lae Sangkhom. 1994 Jan;5(1-2):31-54.

PMID:
12291433
27.
28.
31.

Population and environment in the hills of Nepal.

Thapa GB, Weber KE.

Asia Pac Popul J. 1989 Jun;4(2):49-70.

PMID:
12316024
32.

Resettlement experiences and alternatives in Thailand.

Thapa GB, Weber KE.

Singap J Trop Geogr. 1988 Dec;9(2):141-50.

PMID:
12281721
33.

Timing of endoreduplication induced by colcemid or radiation in BUdR-labeled human lymphocytes.

Weber KE, Hoegerman SF.

Exp Cell Res. 1980 Jul;128(1):31-9. No abstract available.

PMID:
7408984
34.

Freezing squash preparations with a freeze-dryer immersion coil apparatus.

Hoegerman SF, Weber KE.

Stain Technol. 1979 Jan;54(1):49-50. No abstract available.

PMID:
483330

Supplemental Content

Loading ...
Support Center